Corona
The collected information (brief, optional): [1] After percutaneous coronary intervention (PCI), dual
The ongoing evolution of SARS-CoV-2 necessitates regular updates to COVID-19 vaccines for at-risk populations due to the virus’s ability to escape pre-existing antibodies [2]. These monovalent variant-specific boosters aim to redirect immune responses, though challenges like immune imprinting can affect the induction of new responses [2].
Summary of the Trend
Recent advancements indicate a trend towards re-evaluating established treatment protocols and refining risk assessment in cardiovascular health, particularly concerning coronary artery disease. Studies are increasingly exploring shorter durations for dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI), moving away from standard 6-12 month recommendations towards regimens as short as 1-3 months [1]. While these abbreviated DAPT courses have shown non-inferiority for net adverse clinical events, especially for patients without high bleeding risk where 3-month DAPT was superior for bleeding compared to 12 months, questions persist regarding their long-term protection against major adverse cardiac or cerebrovascular events [1, 3]. Simultaneously, the integration of polygenic risk scores (PRS) is emerging as a method to personalize primary prevention for major adverse cardiovascular events, demonstrating that statin effectiveness is more pronounced in individuals with higher polygenic risk for coronary artery disease [6].
Concurrently, the landscape of public health continues to be shaped by the evolving nature of SARS-CoV-2 and its impact on vaccine strategies. Due to the virus’s ability to escape pre-existing antibodies, there is a persistent need for yearly COVID-19 vaccine updates, especially for at-risk populations [2]. Monovalent variant-specific booster vaccines, such as those targeting XBB.1.5, are designed to redirect immune responses; however, immune imprinting from prior exposures to the ancestral spike protein can potentially limit the effectiveness of inducing de novo immune responses to new variants [2]. Post-vaccination, memory T- and B-cell responses, along with antibodies, are boosted for up to six months, yet neutralizing antibodies for current Omicron subvariants remain lower than those for the ancestral strain, despite being preferentially boosted [2].
Critical Analysis
Despite the necessity of yearly COVID-19 vaccine updates to address ongoing viral escape from pre-existing antibodies, a significant challenge arises from immune imprinting [2]. Prior exposures to the ancestral SARS-CoV-2 spike protein can hinder the effective induction of de novo immune responses against antigenically distinct variants [2]. Consequently, while monovalent variant-specific boosters can boost memory T- and B-cell responses and antibodies, neutralizing antibodies targeting Omicron subvariants circulating at the time of vaccination remain preferentially lower than those against the ancestral strain for up to six months post-vaccination [2]. This suggests a limitation in fully redirecting the immune system to optimally tackle newer, evolving threats.
Furthermore, while viral recombination is widely considered a potent driver of SARS-CoV-2 adaptation, its overall contribution to fitness gains is complex and often overestimated [7]. Although the rate of detectable recombination is primarily driven by the standing viral genetic diversity in the population and, to a lesser extent, by the number of infections, a critical analysis of extensive genomic data reveals a counterintuitive finding [7]. Over 80% of the more than 2,000 recombination events inferred from 16 million SARS-CoV-2 genomes were found to produce viruses with neutral or even reduced fitness [7].
This observation, consistent with the “nearly neutral theory of molecular evolution,” provides a crucial counterpoint to the assumption that all recombination events necessarily lead to more virulent or transmissible strains [7]. The combined challenges of immune imprinting hindering effective de novo immune responses [2] and the predominantly neutral or deleterious outcomes of viral recombination events [7] illustrate the complex biological landscape that vaccine and public health strategies must navigate when confronting a rapidly evolving pathogen like SARS-CoV-2.
Implication for Practice or Policy
Policy makers and healthcare providers must acknowledge the ongoing challenge of SARS-CoV-2 evolution and immune imprinting when planning vaccination strategies [2]. Given the necessity for yearly vaccine updates for at-risk populations and the observation that monovalent variant-specific boosters, while boosting memory T- and B-cell responses and antibodies for up to 6 months, result in neutralizing antibodies for circulating Omicron subvariants that remain lower than for the ancestral strain, it is crucial to continue advocating for regular, updated vaccinations, especially for vulnerable groups [2]. Furthermore, policies should support research into novel vaccine designs that can more effectively overcome immune imprinting to elicit broader and more potent de novo immune responses against evolving SARS-CoV-2 variants.
Closing Reflection
Future medical practices will continue to be shaped by ongoing research and real-world data, leading to refined treatments and prevention strategies. This necessitates continuous adaptation of guidelines and public health initiatives to integrate new evidence and address emerging health challenges effectively.
Signature
Dr Omar Tujjar – MD, MA, MPH, PGDip, EDAIC, EDRA Consultant in Anaesthesia, Intensive Care, and Pain Medicine National Orthopaedic Hospital Cappagh Dublin, Ireland (++353) 085 1781872
